CervoMed to present results on Phase 2b RewinD-LB study

CervoMed (CRVO) announced that investigators plan to present results, including new results, from the Extension phase of the Phase 2b RewinD-LB study that show neflamapimod demonstrated a clinically meaningful effect on slowing clinical progression in patients with DLB in an oral presentation during the 19th International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurologic Disorders on Saturday, April 5, 2025. Positive effects seen with the New Capsules of neflamapimod compared to controls on multiple clinical endpoints: Improvement on primary outcome measures, change in CDR-SB, with the New Capsules both vs. Old Capsules during first 16 weeks of the Extension phase and vs. placebo utilizing all data in the study through to week 32; The magnitude of the effect on the CDR-SB was for all participants a mean improvement of 0.73 points with the New Capsules compared to the Old Capsules, and a mean 0.81 points in participants whose screening plasma ptau181 was less than 2.2 pg/mL, both exceeding the 0.5-point treatment group difference considered to be clinically meaningful; The percentage of participants who had clinically meaningfully worsening during the first 16 weeks of the Extension phase was 40% lower on a relative basis in New Capsule recipients compared to Old Capsule recipients; and 62% lower in participants whose screening plasma ptau181 was less than 2.2 pg/mL; Improvement on Alzheimer’s Disease Cooperative Study-CGIC in participants administered New Capsules both in comparison to Old Capsules during the Extension phase and in a within-participant comparison to placebo treatment during the Initial phase; Based on evaluation of 95% confidence intervals, improvement with New Capsules versus Old Capsules seen on Dementia Cognitive Fluctuation Scale and International Shopping List Test-Recognition; and positive trends were seen on 12-item Neuropsychiatric Inventory, Timed Up and Go and Unified Parkinson’s Disease Rating Scale Part III